A transitional state of pro-urokinase that has a higher catalytic efficiency against glu-plasminogen than urokinase
- PMID: 1639775
A transitional state of pro-urokinase that has a higher catalytic efficiency against glu-plasminogen than urokinase
Abstract
Plasminogen activation by single-chain urokinase-type plasminogen activator or pro-urokinase (pro-UK) is accompanied by the generation of two-chain urokinase (UK) by plasmin which provides a positive feedback. In the present study, the time course of the activation of Glu-plasminogen and of Lys-plasminogen (10 microM) by pro-UK (1.0 nM) was studied. In the presence of native plasminogen (Glu-plasminogen), three distinct phases with different rates of plasmin generation were observed. The initial phase was slow and corresponded to the intrinsic activity of pro-UK as reflected by the activity of a plasmin-resistant mutant (Lys158----Ala). This was followed by a second phase which had the most rapid rate. The third phase had a plasminogen activation rate which was significantly slower than the second and paralleled the rate of activation by UK (1.0 nM). The second phase coincided with the time at which there was only about 50% conversion of pro-UK to UK, whereas the final phase coincided with essentially complete conversion. In the presence of fibrin fragment E-2 (20 microM), previously shown to strongly promote plasminogen activation by pro-UK, the identical phenomenon was observed, but at one-tenth the concentration of pro-UK. The most rapid rate of plasmin generation again coincided with transitional (25-60%) pro-UK to UK conversion. To further examine this phenomenon, the rate of pro-UK to UK conversion was controlled by using kallikrein in the presence of a plasmin inhibitor. In this experiment, the activation of Glu-plasminogen bound to solid-phase fibrin was measured. A similar three-phase sequence was observed, the highest rate of plasmin generation coinciding with about 45% conversion of pro-UK to UK. A mechanism for this transitional state phenomenon was postulated based on the established significantly higher affinity of pro-UK than of UK for Glu-plasminogen. This exceptional property for a proenzyme may enable a transient activity to be generated during the transition from pro-UK to UK corresponding to the more favorable KM of pro-UK and the kcat of UK. This hypothesis was supported by the results from experiments in which Lys-plasminogen was substituted for the Glu form. No transitional state activity was observed, consistent with the relatively high KM of pro-UK against Lys-plasminogen.
Similar articles
-
Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK.Biochemistry. 1992 Jul 14;31(27):6311-7. doi: 10.1021/bi00142a021. Biochemistry. 1992. PMID: 1385727
-
Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.Eur J Biochem. 1988 Nov 15;177(3):575-82. doi: 10.1111/j.1432-1033.1988.tb14409.x. Eur J Biochem. 1988. PMID: 2973984
-
The effects of fibrinogen and its cleavage products on the kinetics of plasminogen activation by urokinase and subsequent plasmin activity.J Biol Chem. 1983 Oct 25;258(20):12171-7. J Biol Chem. 1983. PMID: 6226655
-
Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).J Clin Invest. 1988 Dec;82(6):1956-62. doi: 10.1172/JCI113815. J Clin Invest. 1988. PMID: 2974047 Free PMC article.
-
Activation of fibrin-bound plasminogen by pro-urokinase and its complementariness with that by tissue plasminogen activator.Enzyme. 1988;40(2-3):97-108. doi: 10.1159/000469151. Enzyme. 1988. PMID: 2971533 Review.
Cited by
-
Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.J Thromb Thrombolysis. 2017 Aug;44(2):210-215. doi: 10.1007/s11239-017-1514-0. J Thromb Thrombolysis. 2017. PMID: 28600623
-
Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK.PLoS One. 2015 Mar 26;10(3):e0122018. doi: 10.1371/journal.pone.0122018. eCollection 2015. PLoS One. 2015. PMID: 25811605 Free PMC article.
-
Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement.J Thromb Thrombolysis. 2015 Nov;40(4):480-7. doi: 10.1007/s11239-015-1217-3. J Thromb Thrombolysis. 2015. PMID: 25894475 Free PMC article. Review. No abstract available.
-
Molecular basis of thrombolytic therapy.J Nucl Cardiol. 2000 Jul-Aug;7(4):373-81. doi: 10.1067/mnc.2000.108608. J Nucl Cardiol. 2000. PMID: 10958280 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources